OOIR: Observatory of International Research

Papers

(The TQCC of Endocrine Reviews is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Erratum to: “The Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens”	260
Effects of maternal vitamin D supplementation on childhood health	219
The Congenital and Acquired Mechanisms Implicated in the Etiology of Central Precocious Puberty	207
How Protein Methylation Regulates Steroid Receptor Function	190
Papillary Craniopharyngioma: An Integrative and Comprehensive Review	160
The Weight of Place: Built Environment Correlates of Obesity and Diabetes	145
Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas	137
Preclinical Rodent Models for Human Bone Disease, Including a Focus on Cortical Bone	135
New and Consolidated Therapeutic Options for Pubertal Induction in Hypogonadism: In-depth Review of the Literature	134
History of Adrenal Research: From Ancient Anatomy to Contemporary Molecular Biology	133
Endocrine Manifestations and New Developments in Mitochondrial Disease	128
Time-restricted Eating for the Prevention and Management of Metabolic Diseases	112
Considering Sex as a Biological Variable in Basic and Clinical Studies: An Endocrine Society Scientific Statement	92
The Changing Face of Turner Syndrome	87
The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives	84
Epigenetic Dysregulation in Endometriosis: Implications for Pathophysiology and Therapeutics	77
Contemporary Biological Insights and Clinical Management of Craniopharyngioma	77
Phosphorylation-Dependent Regulation of Guanylyl Cyclase (GC)-A and Other Membrane GC Receptors	69
The Role of Iodine for Thyroid Function in Lactating Women and Infants	67
Personalized Management of Pheochromocytoma and Paraganglioma	66
Risks of Iodine Excess	61
Teprotumumab for the Treatment of Thyroid Eye Disease	61
Biomarkers to Guide Medical Therapy in Primary Aldosteronism	59
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management	58
The Spectrum of the Prader–Willi-like Pheno- and Genotype: A Review of the Literature	54

Corrigendum to: Personalized Management of Pheochromocytoma and Paraganglioma	54
Diabetes Mellitus, Energy Metabolism, and COVID-19	53
Correction to: “Brown Adipose Tissue—A Translational Perspective”	53
Update on Adipose Tissue and Cancer	53
A State of Natriuretic Peptide Deficiency	50
Correction to: “ER Stress in Cardiometabolic Diseases: From Molecular Mechanisms to Therapeutics”	48
Growth Hormone Action as a Target in Cancer: Significance, Mechanisms, and Possible Therapies	48
Metformin, Cognitive Function, and Changes in the Gut Microbiome	47
Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia	45
Insulin: A 100-Year-Old Discovery With a Fascinating History	42
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs	41
Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments	40
Macrophage Responses to Environmental Stimuli During Homeostasis and Disease	40